APOPTOSIS
Entity Detail — Knowledge Graph Node
Understanding Entity Pages
This page aggregates everything SciDEX knows about APOPTOSIS: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
Summary
Apoptosis is programmed cell death essential for normal development and tissue homeostasis. In neurodegeneration, aberrant activation of apoptotic pathways contributes to neuronal loss. Key mediators include caspases, Bcl-2 family proteins, cytochrome c, and death receptors. Both intrinsic (mitochondrial) and extrinsic (death receptor) pathways are implicated in diseases like Alzheimer's, Parkinson's, and ALS.
AI-generated illustration · click image to enlarge
Regenerate portrait ↻Wiki Pages (1)
Knowledge base pages for this entity
Pathway Diagram
graph TD
subgraph Pathology["Pathology"]
APOPTOSIS["APOPTOSIS"] -->|"causes"| NEURODEGENERATION["NEURODEGENERATION"]
APOPTOSIS["APOPTOSIS"] -->|"associated with"| NLRP3["NLRP3"]
APOPTOSIS["APOPTOSIS"] -->|"associated with"| MICROGLIA["MICROGLIA"]
APOPTOSIS["APOPTOSIS"] -->|"associated with"| NEURON["NEURON"]
APOPTOSIS["APOPTOSIS"] -->|"associated with"| APP["APP"]
APOPTOSIS["APOPTOSIS"] -->|"associated with"| GFAP["GFAP"]
BECN1["BECN1"] -->|"associated with"| APOPTOSIS["APOPTOSIS"]
AMYLOID["AMYLOID"] -->|"associated with"| APOPTOSIS["APOPTOSIS"]
end
subgraph Signaling["Signaling"]
APOPTOSIS["APOPTOSIS"] -.->|"inhibits"| CANCER["CANCER"]
APOPTOSIS["APOPTOSIS"] -->|"activates"| Lymphoma["Lymphoma"]
APOPTOSIS["APOPTOSIS"] -->|"activates"| Apoptosis["Apoptosis"]
MITOPHAGY["MITOPHAGY"] -->|"activates"| APOPTOSIS["APOPTOSIS"]
AUTOPHAGY["AUTOPHAGY"] -->|"regulates"| APOPTOSIS["APOPTOSIS"]
AKT["AKT"] -.->|"inhibits"| APOPTOSIS["APOPTOSIS"]
INFLAMMATION["INFLAMMATION"] -->|"activates"| APOPTOSIS["APOPTOSIS"]
end
style APOPTOSIS fill:#5d4400,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0,font-weight:bold
style NEURODEGENERATION fill:#5d4400,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style CANCER fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style NLRP3 fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style MICROGLIA fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style NEURON fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style APP fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style GFAP fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style Lymphoma fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style Apoptosis fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style BECN1 fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style AMYLOID fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style MITOPHAGY fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style AUTOPHAGY fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style AKT fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
style INFLAMMATION fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0Outgoing (5305)
| Target | Relation | Type | Str |
|---|---|---|---|
| Differentiation | regulates | pathway | 1.00 |
| Metastasis | regulates | pathway | 1.00 |
| Pi3K/Akt | regulates | pathway | 1.00 |
| Metastasis | activates | pathway | 1.00 |
| JNK | activates | gene | 1.00 |
| Microrna | regulates | pathway | 1.00 |
| DNA | regulates | gene | 1.00 |
| Infection | regulates | disease | 1.00 |
| MITOCHONDRIA | regulates | gene | 1.00 |
| Chemoresistance | activates | pathway | 1.00 |
| Angiogenesis | activates | pathway | 1.00 |
| Senescence | regulates | disease | 1.00 |
| MDM2 | activates | gene | 1.00 |
| Tumor | expressed_in | disease | 1.00 |
| Pi3K/Akt | inhibits | pathway | 1.00 |
| Lipid Metabolism | activates | pathway | 1.00 |
| MITOCHONDRIA | activates | gene | 1.00 |
| Cell Cycle | activates | pathway | 1.00 |
| Stroke | associated_with | disease | 1.00 |
| Carcinoma | inhibits | disease | 1.00 |
| Alzheimer | regulates | disease | 1.00 |
| Mapk | inhibits | pathway | 1.00 |
| Cardiovascular | therapeutic_target | disease | 1.00 |
| Pyroptosis | regulates | pathway | 1.00 |
| Neurodegeneration | regulates | disease | 1.00 |
| BCL-2 | regulates | gene | 1.00 |
| Lymphoma | inhibits | disease | 1.00 |
| Diabetes | activates | disease | 1.00 |
| Cancer | expressed_in | disease | 1.00 |
| Alzheimer | inhibits | disease | 1.00 |
| NEURODEGENERATION | causes | phenotype | 1.00 |
| APP | activates | gene | 1.00 |
| NRF2 | associated_with | gene | 1.00 |
| Aging | therapeutic_target | disease | 1.00 |
| GFAP | associated_with | gene | 1.00 |
| APP | associated_with | gene | 1.00 |
| Ferroptosis | regulates | pathway | 1.00 |
| Mapk | therapeutic_target | pathway | 1.00 |
| Als | expressed_in | disease | 1.00 |
| Inflammation | therapeutic_target | disease | 1.00 |
| NEURODEGENERATIVE DISEASES | activates | gene | 1.00 |
| Lymphoma | therapeutic_target | disease | 1.00 |
| Apoptosis | inhibits | pathway | 1.00 |
| Ischemia | regulates | disease | 1.00 |
| Stroke | regulates | disease | 1.00 |
| STING | activates | gene | 1.00 |
| CANCER | inhibits | disease | 1.00 |
| Ferroptosis | inhibits | pathway | 1.00 |
| Carcinoma | activates | disease | 1.00 |
| Lung Cancer | activates | disease | 1.00 |
Incoming (7036)
| Source | Relation | Type | Str |
|---|---|---|---|
| INFLAMMATION | inhibits | gene | 1.00 |
| NEURODEGENERATIVE DISEASES | regulates | gene | 1.00 |
| OXIDATIVE STRESS | therapeutic_target | gene | 1.00 |
| AUTOPHAGY | inhibits | gene | 1.00 |
| INFLAMMATION | therapeutic_target | gene | 1.00 |
| ALZHEIMER'S DISEASE | therapeutic_target | gene | 1.00 |
| EGFR | therapeutic_target | gene | 1.00 |
| OXIDATIVE STRESS | activates | gene | 1.00 |
| Inflammation | activates | disease | 1.00 |
| CANCER | inhibits | gene | 1.00 |
| BAX | therapeutic_target | gene | 1.00 |
| FERROPTOSIS | inhibits | gene | 1.00 |
| Cancer | regulates | disease | 1.00 |
| MTOR | inhibits | gene | 1.00 |
| OVERVIEW | therapeutic_target | gene | 1.00 |
| HO-1 | activates | gene | 1.00 |
| P53 | activates | gene | 1.00 |
| Parkinson | activates | disease | 1.00 |
| ERK | inhibits | gene | 1.00 |
| Aging | therapeutic_target | disease | 1.00 |
| BECN1 | associated_with | gene | 1.00 |
| Diabetes | activates | disease | 1.00 |
| TP53 | activates | gene | 1.00 |
| Carcinoma | inhibits | disease | 1.00 |
| SQSTM1 | activates | gene | 1.00 |
| NEURODEGENERATION | regulates | gene | 1.00 |
| STAT3 | activates | gene | 1.00 |
| Tumor | activates | disease | 1.00 |
| Neurodegeneration | regulates | disease | 1.00 |
| GENES | therapeutic_target | gene | 1.00 |
| PARKIN | activates | gene | 1.00 |
| Aging | activates | disease | 1.00 |
| Als | therapeutic_target | disease | 1.00 |
| TNF | inhibits | gene | 1.00 |
| BDNF | activates | gene | 1.00 |
| NRF2 | activates | gene | 1.00 |
| PINK1 | activates | gene | 1.00 |
| Carcinoma | therapeutic_target | disease | 1.00 |
| MTOR | activates | gene | 1.00 |
| JUN | activates | gene | 1.00 |
| PTEN | activates | gene | 1.00 |
| TNF | activates | gene | 1.00 |
| MTOR | regulates | gene | 1.00 |
| Neuroinflammation | activates | disease | 1.00 |
| TNF | therapeutic_target | gene | 1.00 |
| BAX | inhibits | gene | 1.00 |
| GENES | activates | gene | 1.00 |
| AUTOPHAGY | activates | gene | 1.00 |
| MTOR | therapeutic_target | gene | 1.00 |
| RAS | activates | gene | 1.00 |
Targeting Hypotheses (3)
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| ATM Kinase Hyperactivation Triggers DNA Damage Response Over | 0.837 | ALS | - |
| Apoptosis-Senescence Decision Point Intervention | 0.649 | - | Senescent cell clearance as neurodegener |
| Colonic Th17/IL-17A Axis → Peripheral Immune Recruitment to | 0.640 | neurodegeneration | What are the mechanisms by which gut mic |
Mentioning Analyses (6)
Scientific analyses that reference this entity
Does RGS6 upregulation or D2 autoreceptor modulation prevent neurodegeneration i
neurodegeneration | 2026-04-25 | 5 hypotheses Top: 0.530
What evidence supports Cdk5 activation as THE primary cause of AD versus other e
neurodegeneration | 2026-04-10 | 0 hypotheses
Can nanobodies achieve selective membrane penetration into tau-containing vesicl
molecular biology | 2026-04-09 | 7 hypotheses Top: 0.455
What determines organelle-specific autophagy selectivity in neurodegenerative di
neurodegeneration | 2026-04-08 | 2 hypotheses Top: 0.580
How does controlled lysosomal membrane permeabilization induce autophagy without
neurodegeneration | 2026-04-07 | 7 hypotheses Top: 0.690
Experiments (1)
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| dilncRNA-mediated molecular crowding and phase separation | exploratory | 0.900 | 0.00 | cultured cells | proposed | N/A |
Related Papers (1)
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Metformin and its potential influence on cell fate decision between apoptosis an [PMID:39267853] | ["Hajimohammadebrahim-Ketabforoush M", " | Front Oncol | 2024 | 0 |
Debates (10)
Multi-agent debates referencing this entity
Extended debate: CYP46A1 Overexpression Gene Therapy
closed · Rounds: 6 · Score: 0.95 · 2026-04-27
Hypothesis debate: Membrane Cholesterol Gradient Modulators
closed · Rounds: 4 · Score: 0.50 · 2026-04-27
Hypothesis debate: Selective Acid Sphingomyelinase Modulation Therapy
closed · Rounds: 4 · Score: 0.40 · 2026-04-27
Hypothesis debate: CYP46A1 Overexpression Gene Therapy
closed · Rounds: 4 · Score: 0.40 · 2026-04-27
Does RGS6 upregulation or D2 autoreceptor modulation prevent neurodegeneration i
closed · Rounds: 4 · Score: 0.54 · 2026-04-25
The study shows trehalose causes lysosomal membrane permeabilization (LMP) that
closed · Rounds: 4 · Score: 0.61 · 2026-04-21
The review covers various organelle-specific autophagy types but doesn't address
closed · Rounds: 4 · Score: 0.66 · 2026-04-21
The abstract claims Cdk5 activation is the primary cause of AD, contradicting th
closed · Rounds: 4 · Score: 0.50 · 2026-04-20
Investigate how lipid raft composition (cholesterol metabolism, sphingolipids) c
closed · Rounds: 5 · Score: 0.93 · 2026-04-11
Can nanobodies achieve selective membrane penetration into tau-containing vesicl
closed · Rounds: 4 · Score: 0.95 · 2026-04-10
Related Research
Hypotheses and analyses mentioning APOPTOSIS in their description or question text
No additional research found